SUPN

#1841
Supernus Pharmaceuticals, Inc. - Common Stock
43.7 3 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
43.73
43.73
Intervallo Annuale
42.45
59.68
Variazione giornaliera
-1.04%
Variazione Mensile
-13.32%
Variazione di 6 mesi
-19.00%
Variazione Annuale
-19.02%
Chiusura Precedente
44.1 9
Open
43.7 3
Minimo
43.7 3
Massimo
43.7 3
Volume
115
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Supernus Pharmaceuticals, Inc. (SUPN) filed a Current Report on Form 8-K dated May 17, 2026. The filing addresses the achievement of a specific milestone under a Contingent Value Right (CVR) Agreement entered into on July 30, 2025.

Key Financial Metrics

  • Milestone Payment Obligation: Approximately $33.4 million in aggregate cash.
  • Payment Rate: $0.50 per Contingent Value Right.
  • Payment Terms: Payable in cash without interest, subject to applicable withholding taxes.
  • Liquidity Impact: The Company is obligated to deposit the necessary funds with the Rights Agent within 20 business days of the Notice Date (May 17, 2026).
  • Other Metrics: The filing does not provide data on revenue, profit, operating cash flow, margins, or total debt levels.

Material Changes

The primary material change is the triggering of a direct financial obligation. On March 18, 2026, Milestone 1 defined in the CVR Agreement was achieved. Consequently, the Company has moved from a contingent liability status to a confirmed obligation to pay the $33.4 million milestone.

Outlook, Risks, and Management Commentary

The filing contains standard forward-looking statements regarding plans and strategies, noting that actual results may differ due to risks and uncertainties. The Company references risk factors detailed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. No specific guidance on future revenue or earnings is provided in this document.

Investor Verification Checklist

  • Verify the Company's current cash and cash equivalents to assess the immediate liquidity impact of the $33.4 million payment due within 20 business days.
  • Review the full text of the CVR Agreement (Exhibit 10.1) to understand the definitions of subsequent milestones and potential future payment obligations.
  • Confirm the number of outstanding CVRs to validate the $33.4 million aggregate calculation.
  • Check the Company's most recent 10-K or 10-Q for updated debt covenants that may be affected by this cash outflow.

Notizie